Search
Texas Paid Clinical Trials
A listing of 4879 clinical trials in Texas actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2737 - 2748 of 4879
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Popular Cities
Texas is currently home to 4879 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Recruiting
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2025
Locations: Prime Revival Research, Coppell, Texas
Conditions: Difficult to Control Hypertension
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Recruiting
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: National Neuromuscular Research Institute, Austin, Texas
Conditions: Myasthenia Gravis
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Recruiting
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/31/2025
Locations: UT Dell Medical School- Ascension, Austin, Texas
Conditions: Type B Aortic Dissection
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: MD Anderson, Houston, Texas
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
Recruiting
To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer
Busulfan Sample Collection Study
Recruiting
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
Gender:
ALL
Ages:
All
Trial Updated:
03/31/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Subjects Treated With Busulfan
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Recruiting
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Kerwin Research and Memory Center, Dallas, Texas
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Recruiting
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Dren Investigational Site, Houston, Texas
Conditions: LGLL - Large Granular Lymphocytic Leukemia, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Recruiting
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Gender:
ALL
Ages:
1 year and above
Trial Updated:
03/31/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Propionic Acidemia
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Recruiting
This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cancer participants with normal renal function as matched control participants. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: MD Anderson, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Recruiting
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and severe hepatic impairment and cancer participants with normal hepatic function as control participants. Participants with severe hepatic impairment will be enrolled only after the safety evaluation of at... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: MD Anderson, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
2737 - 2748 of 4879
A clinical trial is conducted when a researcher finds a potential new drug, medical device, surgical procedure or intervention that has the potential of improving the lives of many but still needs to be tested to see if it is effective and safe for humans. In the state of Texas, there are a number of paid clinical trials for willing participants.
Clinical trials can last for many years because the medication or the intervention needs to be tested on many participants to ensure its safety and effectiveness. Many hospitals such as the Houston Methodist Hospital in Houston, Texas conduct clinical trials especially to find new treatments for diseases such as cancer, heart disease, and hormonal conditions. Hospitals tend to recruit participants by informing patients of the research study inviting them to participate.
On the other hand, pharmaceutical companies that develop new medications or medical devices sometimes need to hire companies to conduct all the different stages of clinical trials for them. These companies are called contract research organizations or CROs.
CROs provide management and support for institutions that need to conduct clinical trials but don't have the expertise or infrastructure to do so. CROs are responsible for recruiting the participants for the study, monitoring the trials, and ensuring that all parts of the study are being conducted according to protocol.
In Texas, there are several CROs that actively recruit volunteers year-round to participate in clinical trials. Some of the major CROs in Texas include: Covance, PPD, and Clinical Trials of Texas.
Search Clinical Trials in Texas by Condition
See All Conditions